Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)

Study acronym: GEMA-proN
StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date changed from estimate of May 15, 2025 to Jul 15, 2026
    • Trial completed
    • Publications: details revised at 5 of 5 entries
    • Eligibility criteria expanded, about 3 words
  2. Eligibility criteria shortened, about 9 words
    • Secondary endpoints revised (2)
    • Study description shortened, about 3 words
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GEMA-proN is an observational, multicenter, single cohort, retrospective clinical trial. The aim of the trial is to assess the prevalence, and prognostic value of genetic molecular alterations and investigate correlations with clinicopathological features in unselected patients with histologically confirmed non-small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT06876402
Lead Sponsor Hellenic Cooperative Oncology Group
Conditions
(from sponsor)		 NSCLC (Non-small Cell Lung Cancer)
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 367 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov